Select Page
Hoth Therapeutics: Orphan Drug Designation for HT-KIT

Hoth Therapeutics: Orphan Drug Designation for HT-KIT

Hoth Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to HT-KIT to treat mastocytosis. Mastocytosis is a rare condition caused by an abnormal accumulation and activation of mast cells in the skin, bone...